Benitec Biopharma Discloses Q1 2022 Financial Results

HAYWARD, Calif.: HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the financial results for its Fiscal Year Q1 ended September 30,...

Click to view original post